Truist initiated coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $14 price target Fulcrum Therapeutics has shown early signs that pociredir could be competitive in the SCD therapeutic landscape, the analyst tells investors in a research note. Encouraging data from the phase Ib PIONEER study for pociredir shows notable induction of HbF, most recently in patients dosed with 12 mg of drug, which in July showed robust and clinically meaningful absolute mean fetal hemoglobin HbF induction of 8.6% from baseline at 12 weeks, and safety continues to remain in-line with previous dosing cohorts and healthy volunteer data, the firm says.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
- Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors
- Fulcrum’s pociredir shows promising early efficacy vs. mitapivat, says Leerink
- Oppenheimer not surprised by Agios data, continues to favor Fulcrum approach
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls